Dexcom
Dexcom, Inc., a leading player in the diabetes care industry, is headquartered in the United States. Founded in 1999, the company has pioneered continuous glucose monitoring (CGM) technology, significantly enhancing diabetes management for patients worldwide. With a strong presence in North America, Europe, and Asia, Dexcom focuses on developing innovative solutions that empower individuals to take control of their health. The company's flagship products, including the Dexcom G6 and G7 CGM systems, offer real-time glucose monitoring with exceptional accuracy and ease of use. These devices are distinguished by their ability to provide users with actionable insights, helping to prevent hypoglycaemic events and improve overall glycaemic control. Dexcom's commitment to innovation has solidified its position as a market leader, recognised for its contributions to diabetes management and patient care.
DitchCarbon Score
How does Dexcom's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dexcom's score of 26 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Dexcom's reported carbon emissions
In 2023, Dexcom reported total carbon emissions of approximately 25,291,000 kg CO2e, comprising Scope 1 emissions of about 5,283,000 kg CO2e (including 1,983,000 kg CO2e from mobile combustion and 3,400,000 kg CO2e from stationary combustion), and Scope 2 emissions of approximately 25,291,000 kg CO2e. Additionally, Scope 3 emissions included about 5,748,000 kg CO2e from business travel and 1,776,000 kg CO2e from waste generated in operations. Over the previous years, Dexcom's emissions have shown a trend of increase, with 2022 emissions at approximately 13,610,000 kg CO2e for Scope 2 and 3, and 11,807,000 kg CO2e in 2021. The company has committed to near-term reduction targets, although it has not set a net-zero target as of now. Dexcom's commitment to reducing its carbon footprint aligns with industry standards, reflecting a growing focus on sustainability within the healthcare equipment sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 1,903,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,371,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 1,257,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dexcom is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
